Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
3M shares sold in late trading - who and why?
Https://twitter.com/Share_Talk/status/1762809896112992478?t=pTWBoYnYbTvXTogPoGrNqg&s=19
I see the Bod fully committed on personal multi million funds within this company and working hard to align multiple rcts to fulfill guidance set out by governing bodies to prove pain relief is controlled within different conditions by real data collected which will be better all round for patients and The NHS on its current spend with out success! Timing is every and perhaps your buys time wise weren't the best! As for the temporary haul on the grow facility at mid stage, this turns out to be a masterclass as we are now going to continue on 3rd party funding instead of our own! Pretty smart business model all round I'd say on the stabilisation side and rct's whilst retaining all ip and commercial rights!
I too have much dwindled pot pompey , if as i now suspect this is a life style comp taking us for fools , i expect a consolidation next then a share issue and bye bye rest [which is only 20% left] of pot ,and before anyone says why dont you f off then ,it aint worth bothering about ,when 80% has slid away already ,written off ,but just maybe i am wrong ,
Haven't posted for some time but still hold a much dwindled pot. I'm still upbeat about the company but I was disappointed when it suddenly announced it was becoming pharma, rather than farmer. I've my fingers crossed for the pharma stuff but it hasn't excited like the 200 tonnes of cannabis they said they were going to grow in a big new facility with djt. With a pure micro pharma play now, I can't help thinking I bought in 10 years too soon. Hope I'm wrong, but good luck all us LTHs.
All signed ! Very nice many more to come I'd say
Should see some great new investor exposure I'd Say!
Maybe they burn some old hemp for heating
Great listen
With proven track records within the organizations they work in.
We have already seen some excellent sector analysis which has been acted on.
We are now building our future on 3rd party money which is a masterclass move.
Medical cannabis drugs are not going away.
Those that currently use know they work.
Existing data sets and trials will put that In black and white.
Nhs is screaming out to treat chronic pain successfully at less cost.
I'm very very Bullish........
No point in selling 10k now 3k .
I hope your right , I won't hold me breath tho
If there was a big back ground buy, because boy is this cheap and whilst weak hands are happy to let some go and mms happy to pay 0.3 on the bid my guess is a buy to show
Deffo a strong hold if you know what your holding, weak hands and the unresearch will moan and groan about the current sp which is expected on low liquidity stocks but the end game will have the sellers weeping! But never mind they can buy their next stock high and sell low lol
This has always been a long term
Investment and we are nearing the end of our wait. Once trials have finished and been approved the sky will be the limit. Patience will be rewarded or sell if not so inclined.
Awarded for what exactly , definitely not for bringing profits to shareholders.
Begging bowl looms
Https://twitter.com/AnandaPlc/status/1757328119168405995?t=mylXCotkAzGOep21tp-ulA&s=19
Yup you and me suckered in ,£1 and 80p ,stupid stupid boy i never learn ,life style comp all day long
I bought this share in 2019 when medical cannabis was the buzz word .
0.80 I paid .
One peep said the ceo is Ponzi scheme artist
Wish I listened
We are certainly building out a company with a wealth of experience and proffession on board in order to become medical leader right here in the uk and beyond to serve this very much emerging sector in order to feed the NHS with hard evidence first then medicines as a result
'His expertise in big data will enable Ananda to assess patient populations in areas of unmet need and support new cannabinoid drug development. Vitalii's focus will be on creating a database of over 10,000 diseases which have symptoms for which cannabinoids may have potential for activity. The database will then be refined to conditions which have evidence that cannabidiol has treatment potential. Refinement and interrogation will provide Ananda with information sets to identify clinical trial research opportunities.'
Looks to be gearing up for next stage objectives.
Biography
Vitalii holds a Master of Business Administration from the Kyiv University of Technology and Design, where he majored in Computer Science and minored in Behavioural Psychology. Vitalii has nine years of experience in the technology sector, beginning his career as a Data Engineer and Solution Architect for several Israeli companies. He has also been a foundational engineer in various start-ups, bringing his unique perspective and technical skills to the forefront of innovation. Vitalii currently works at an investment fund, where he creates quantitative models and tools to support investment decisions.
To stay up to date with the latest developments at Ananda, we encourage you to follow and join our social media channels which are:
· Register at our Investor Hub: https://investors.anandadevelopments.com/s/a66906
· Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
· LinkedIn: https://www.linkedin.com/company/anadevelopments/
· Twitter: https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor
-Ends-
Today 07:00
RNS Number : 0542C
Ananda Developments PLC
06 February 2024
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Ananda Appoints Data and Analytics Expert
Ananda Developments Plc ('Ananda'), a company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions, is pleased to announce the appointment of Vitalii Ratushnyi as an adviser to the Company with a focus on data and analytics.
Vitalii is a data, analytics, and quantitative modelling expert. His appointment gives Ananda the analytical capability to better target its research activities by identifying potential current and new disease areas where cannabinoids may be efficacious. His expertise in big data will enable Ananda to assess patient populations in areas of unmet need and support new cannabinoid drug development. Vitalii's focus will be on creating a database of over 10,000 diseases which have symptoms for which cannabinoids may have potential for activity. The database will then be refined to conditions which have evidence that cannabidiol has treatment potential. Refinement and interrogation will provide Ananda with information sets to identify clinical trial research opportunities. The Company's objective is to provide the evidence required to get cannabis-based medicines available on the NHS.
Ananda CEO Melissa Sturgess commented "We believe our ability to get to grips with large biological and genetic data sets will help us find opportunities for our cannabinoid medicines, guide the design of clinical trials and will be a cornerstone of our success. This work is critical for the rapid development of our clinical trials pipeline and intellectual property estate."
Biog...